Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis

Molecular Pharmaceutics

Volumn 7, Issue 6, 2010, Pages 2020-2029

  Lobatto, Mark E ^a   Fayad, Zahi A ^a   Silvera, Stephane ^a   Vucic, Esad ^a   Calcagno, Claudia ^a   Mani, Venkatesh ^a   Dickson, Stephen D ^a   Nicolay, Klaas ^b   Banciu, Manuela ^c   Schiffelers, Raymond M ^c   Metselaar, Josbert M ^c   Van Bloois, Louis ^c   Wu, Hai Shan ^a   Fallon, John T ^a   Rudd, James H ^a,d   Fuster, Valentin ^e,f   Fisher, Edward A ^g   Storm, Gert ^c   Mulder, Willem J M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE SODIUM PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MACROPHAGE; MALE; MORBIDITY; MORTALITY; NANOIMAGING; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RABBIT; SYSTEMIC DISEASE; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLUCOCORTICOIDS; LIPOSOMES; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NANOMEDICINE; POSITRON-EMISSION TOMOGRAPHY; RABBITS;

EID: 78649932571     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100309y     Document Type: Article

References (44)

1. Sanz, J.; Moreno, P. R.; Fuster, V. The year in atherothrombosis J. Am. Coll. Cardiol. 2008, 51, 944-955
2. Fuster, V.; Moreno, P. R.; Fayad, Z. A.; Corti, R.; Badimon, J. J. Atherothrombosis and high-risk plaque: part I: evolving concepts J. Am. Coll. Cardiol. 2005, 46, 937-954
3. Ross, R. Atherosclerosis - an inflammatory disease N. Engl. J. Med. 1999, 340, 115-126
4. Chono, S.; Tauchi, Y.; Deguchi, Y.; Morimoto, K. Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice J. Drug Targeting 2005, 13, 267-276 (Pubitemid 41086291)
5. Lindsay, A. C.; Choudhury, R. P. Form to function: current and future roles for atherosclerosis imaging in drug development Nat. Rev. Drug Discovery 2008, 7, 517-529
6. Choudhury, R. P.; Fuster, V.; Fayad, Z. A. Molecular, cellular and functional imaging of atherothrombosis Nat. Rev. Drug Discovery 2004, 3, 913-925
7. Sanz, J.; Fayad, Z. A. Imaging of atherosclerotic cardiovascular disease Nature 2008, 451, 953-957
8. Poon, M.; Gertz, S. D.; Fallon, J. T.; Wiegman, P.; Berman, J. W.; Sarembock, I. J.; Taubman, M. B. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits Atherosclerosis 2001, 155, 371-380
9. Danenberg, H. D.; Golomb, G.; Groothuis, A.; Gao, J.; Epstein, H.; Swaminathan, R. V.; Seifert, P.; Edelman, E. R. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits Circulation 2003, 108, 2798-2804
10. Czock, D.; Keller, F.; Rasche, F. M.; Haussler, U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids Clin. Pharmacokinet. 2005, 44, 61-98
11. Metselaar, J. M.; Storm, G. Liposomes in the treatment of inflammatory disorders Expert. Opin. Drug Delivery 2005, 2, 465-476
12. Banciu, M.; Schiffelers, R. M.; Fens, M. H.; Metselaar, J. M.; Storm, G. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice J. Controlled Release 2006, 113, 1-8
13. Banciu, M.; Metselaar, J. M.; Schiffelers, R. M.; Storm, G. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice J. Steroid Biochem. Mol. Biol. 2008, 111, 101-110
14. Banciu, M.; Fens, M. H.; Storm, G.; Schiffelers, R. M. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice J. Controlled Release 2008, 127, 131-136
15. Banciu, M.; Metselaar, J. M.; Schiffelers, R. M.; Storm, G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue Neoplasia 2008, 10, 108-117
16. Schmidt, J.; Metselaar, J. M.; Wauben, M. H.; Toyka, K. V.; Storm, G.; Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis Brain 2003, 126, 1895-1904
17. Metselaar, J. M.; Wauben, M. H.; Wagenaar-Hilbers, J. P.; Boerman, O. C.; Storm, G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes Arthritis Rheum. 2003, 48, 2059-2066
18. Delbeke, D. Oncological applications of FDG PET imaging J. Nucl. Med. 1999, 40, 1706-1715
19. Delbeke, D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma J. Nucl. Med. 1999, 40, 591-603
20. Rudd, J. H.; Myers, K. S.; Bansilal, S.; Machac, J.; Pinto, C. A.; Tong, C.; Rafique, A.; Hargeaves, R.; Farkouh, M.; Fuster, V. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations J. Nucl. Med. 2008, 49, 871-878
21. Rudd, J. H.; Warburton, E. A.; Fryer, T. D.; Jones, H. A.; Clark, J. C.; Antoun, N.; Johnstrom, P.; Davenport, A. P.; Kirkpatrick, P. J.; Arch, B. N. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography Circulation 2002, 105, 2708-2711
22. Tawakol, A.; Migrino, R. Q.; Bashian, G. G.; Bedri, S.; Vermylen, D.; Cury, R. C.; Yates, D.; LaMuraglia, G. M.; Furie, K.; Houser, S. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients J. Am. Coll. Cardiol. 2006, 48, 1818-1824
23. Tawakol, A.; Migrino, R. Q.; Hoffmann, U.; Abbara, S.; Houser, S.; Gewirtz, H.; Muller, J. E.; Brady, T. J.; Fischman, A. J. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography J. Nucl. Cardiol. 2005, 12, 294-301
24. Moreno, P. R.; Purushothaman, K. R.; Sirol, M.; Levy, A. P.; Fuster, V. Neovascularization in human atherosclerosis Circulation 2006, 113, 2245-2252
25. Padhani, A. R.; Husband, J. E. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies Clin. Radiol. 2001, 56, 607-620
26. Padhani, A. R. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions J. Magn Reson. Imaging 2002, 16, 407-422
27. Calcagno, C.; Cornily, J. C.; Hyafil, F.; Rudd, J. H.; Briley-Saebo, K. C.; Mani, V.; Goldschlager, G.; Machac, J.; Fuster, V.; Fayad, Z. A. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET Arterioscler., Thromb., Vasc. Biol. 2008, 28, 1311-1317
28. Ogawa, M.; Magata, Y.; Kato, T.; Hatano, K.; Ishino, S.; Mukai, T.; Shiomi, M.; Ito, K.; Saji, H. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques J. Nucl. Med. 2006, 47, 1845-1850
29. Ogawa, M.; Ishino, S.; Mukai, T.; Asano, D.; Teramoto, N.; Watabe, H.; Kudomi, N.; Shiomi, M.; Magata, Y.; Iida, H. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study J. Nucl. Med. 2004, 45, 1245-1250
30. Zhang, Z.; Machac, J.; Helft, G.; Worthley, S. G.; Tang, C.; Zaman, A. G.; Rodriguez, O. J.; Buchsbaum, M. S.; Fuster, V.; Badimon, J. J. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation BMC Nucl. Med. 2006, 6, 3
31. Gu, L.; Okada, Y.; Clinton, S. K.; Gerard, C.; Sukhova, G. K.; Libby, P.; Rollins, B. J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice Mol. Cell 1998, 2, 275-281
32. Salcedo, R.; Ponce, M. L.; Young, H. A.; Wasserman, K.; Ward, J. M.; Kleinman, H. K.; Oppenheim, J. J.; Murphy, W. J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression Blood 2000, 96, 34-40
33. Ogawara, K.; Kuldo, J. M.; Oosterhuis, K.; Kroesen, B. J.; Rots, M. G.; Trautwein, C.; Kimura, T.; Haisma, H. J.; Molema, G. Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene Arthritis Res. Ther. 2006, 8, R32
34. Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discovery Today 2006, 11, 812-818
35. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discovery 2005, 4, 145-160
36. Amirbekian, V.; Lipinski, M. J.; Briley-Saebo, K. C.; Amirbekian, S.; Aguinaldo, J. G.; Weinreb, D. B.; Vucic, E.; Frias, J. C.; Hyafil, F.; Mani, V. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 961-966
37. Mulder, W. J.; Strijkers, G. J.; Habets, J. W.; Bleeker, E. J.; van der Schaft, D. W.; Storm, G.; Koning, G. A.; Griffioen, A. W.; Nicolay, K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle FASEB J. 2005, 19, 2008-2010
38. Winter, P. M.; Morawski, A. M.; Caruthers, S. D.; Fuhrhop, R. W.; Zhang, H.; Williams, T. A.; Allen, J. S.; Lacy, E. K.; Robertson, J. D.; Lanza, G. M. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles Circulation 2003, 108, 2270-2274
39. Tahara, N.; Kai, H.; Ishibashi, M.; Nakaura, H.; Kaida, H.; Baba, K.; Hayabuchi, N.; Imaizumi, T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography J. Am. Coll. Cardiol. 2006, 48, 1825-1831
40. Rudd, J. H.; Myers, K. S.; Bansilal, S.; Machac, J.; Rafique, A.; Farkouh, M.; Fuster, V.; Fayad, Z. A. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials J. Am. Coll. Cardiol. 2007, 50, 892-896
41. Schiffelers, R. M.; Banciu, M.; Metselaar, J. M.; Storm, G. Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer J. Liposome Res. 2006, 16, 185-194
42. Winter, P. M.; Morawski, A. M.; Caruthers, S. D.; Harris, T. D.; Fuhrhop, R. W.; Zhang, H. Y.; Allen, J. S.; Lacy, E. K.; Williams, T. A.; Wickline, S. A. Antiangiogenic therapy of early atherosclerosis with paramagnetic alpha(v)beta(3)-integrin-targeted fumagillin nanoparticles J. Am. Coll. Cardiol. 2004, 43, 322A-323A
43. Hyafil, F.; Cornily, J. C.; Feig, J. E.; Gordon, R.; Vucic, E.; Amirbekian, V.; Fisher, E. A.; Fuster, V.; Feldman, L. J.; Fayad, Z. A. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography Nat. Med. 2007, 13, 636-641
44. Mulder, W. J.; Strijkers, G. J.; Griffioen, A. W.; van Bloois, L.; Molema, G.; Storm, G.; Koning, G. A.; Nicolay, K. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets Bioconjugate Chem. 2004, 15, 799-806